Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GUSB | P08236 | 5/20 | 0.63 |
| ▸ | NPC1 | O15118 | 2/20 | 0.63 |
| ▸ | RAB9A | P51151 | 2/20 | 0.63 |
| ▸ | TNKS | O95271 | 1/20 | 0.63 |
| ▸ | PARP1 | P09874 | 1/20 | 0.63 |
| ▸ | CASP3 | P42574 | 1/20 | 0.63 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.63 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.63 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | ITK | Q08881 | 1/20 | 0.55 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.50 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.50 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.50 |
| ▸ | TUBB | P07437 | 1/20 | 0.50 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.50 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4497587 | 0.82 | TNKS (0.59) | GUSBNPC1RAB9ATNKSPARP1 | |
| SCHEMBL29593104 | 0.78 | TNKS (1.00) | GUSBNPC1RAB9ATNKSPARP1 | |
| SCHEMBL8502164 | 0.78 | TNKS (1.00) | GUSBNPC1RAB9ATNKSPARP1 | |
| SCHEMBL23743251 | 0.78 | GUSB (0.72) | GUSBNPC1RAB9ATNKSPARP1 | |
| SCHEMBL16018013 | 0.78 | GUSB (0.84) | GUSBNPC1RAB9ATNKSPARP1 | |
| SCHEMBL874228 | 0.77 | GUSB (0.73) | GUSBNPC1RAB9ATNKSPARP1 | |
| SCHEMBL29784145 | 0.77 | GUSB (0.73) | GUSBNPC1RAB9ATNKSPARP1 | |
| SCHEMBL28645325 | 0.77 | GUSB (0.77) | GUSBNPC1RAB9ATNKSPARP1 | |
| SCHEMBL16007868 | 0.77 | GUSB (1.00) | GUSBNPC1RAB9ATNKSPARP1 | |
| SCHEMBL4510141 | 0.76 | GUSB (0.60) | GUSBNPC1RAB9ATNKSPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318479-A1 | SUBSTITUTED RING FUSED AZINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED | 2009-12-24 | — | — | US | claimed |
| US-20090318479-A1 | SUBSTITUTED RING FUSED AZINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318479-A1 | SUBSTITUTED RING FUSED AZINES AND THEIR USE IN CANCER THERAPY | TP53, AZI2, MCL1 | GUSB 2378/4885NPC1 1687/4885RAB9A 1026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.